Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degradersnews2025-09-15T11:29:56+00:00September 15th, 2025|Endpoints News|
Lila Sciences is near a $300M+ fundraise to back autonomous science: sourcenews2025-09-13T16:31:09+00:00September 13th, 2025|Endpoints News|
Novo Nordisk’s ongoing challenges; Summit’s Western data disappoint; Eli Lilly offers free AI access to startups; and morenews2025-09-13T10:00:40+00:00September 13th, 2025|Endpoints News|
AstraZeneca halts another UK investment, following Merck and Lilly movesnews2025-09-12T19:37:36+00:00September 12th, 2025|Endpoints News|
Top drug regulator pushes back on report that FDA wants to ‘abandon’ some adcommsnews2025-09-12T18:22:06+00:00September 12th, 2025|Endpoints News|
Lilly loses bid to overturn $183.7M judgment in Medicaid rebate fightnews2025-09-12T15:59:58+00:00September 12th, 2025|Endpoints News|
Lilly’s UK Gateway Labs plans uncertain in new blow to region’s biopharma industrynews2025-09-12T15:19:34+00:00September 12th, 2025|Endpoints News|
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynocnews2025-09-12T14:46:45+00:00September 12th, 2025|Endpoints News|
Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’snews2025-09-12T12:44:58+00:00September 12th, 2025|Endpoints News|
KalVista reports strong sales in early launch of hereditary angioedema drugnews2025-09-12T11:14:43+00:00September 12th, 2025|Endpoints News|
